Efficacy of early treatment with infliximab in pediatric Crohn&rsquo;s disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 14

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

346

HTML

2712

Figures (1-1)

165

Tables (1-4)

161

Sum=3384

Apr 14, 2010 (publication date) through Nov 8, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Apr 14, 2010; 16(14): 1776-1781
Published online Apr 14, 2010. doi: 10.3748/wjg.v16.i14.1776

Table 4 Adverse events

	n (%)	Details
Group A (mesalamine)	3 (30.0)	Anorexia (n = 2), Pancreatitis (n = 1)
Group B (azathioprine)	5 (38.5)	Anorexia (n = 1), Pancytopenia (n = 3), Pancreatitis (n = 1)
Group C (infliximab)	1 (8.3)	Dyspnea and tachycardia (n = 1)

Citation: Lee JS, Lee JH, Lee JH, Lee HJ, Kim MJ, Lee HJ, Choe YH. Efficacy of early treatment with infliximab in pediatric Crohn’s disease. World J Gastroenterol 2010; 16(14): 1776-1781
URL: https://www.wjgnet.com/1007-9327/full/v16/i14/1776.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i14.1776